Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...

(Alliance News) - GSK PLC on Friday announced that Japan has accepted a regulatory application to expand the use of its respiratory syncytial virus [RSV] vaccine Arexvy.

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...

Housebuilder Berkeley posted a 5% fall in annual earnings but said it was confident about the future against a backdrop of falling interest rates and government plans to ramp up supply using ...

GSK’s Arexvy now recommended for adults 50-59 at risk Open in App FLASH SALE Sign In Free Sign Up ...

GSK’s Arexvy now recommended for adults 50-59 at risk ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

GSK’s Arexvy now recommended for adults 50-59 at risk View all comments (0) 0 Latest comments Post Comment Guidelines Trade With A Regulated Broker Indices Commodities Bonds Stocks US 30 41,089. ...

Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's ...